Edgewise Therapeutics, Inc.
EWTX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001710072
In the last 90 days, Edgewise Therapeutics, Inc. insiders filed 0 open-market purchases and 6 sales; 226 institutions reported holding it in 13F filings for Q2 2026, worth $4.82B in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Edgewise Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 6 filings
- 5 insiders, $9.78M in total
- Insiders trading
- 5
- Net value
- −$9.78M
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Edgewise Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Nofi Michael | Chief Financial Officer | – | Aug 17, 2026 | 2 |
| Donovan Joanne M. | CMO | 8,625 | Aug 17, 2026 | 5 |
| Russell Alan J | Chief Scientific Officer | 31,466 | Aug 17, 2026 | 3 |
| Moore John R | General Counsel | 17,697 | Aug 17, 2026 | 1 |
| Derakhshan Behrad | Chief Business Officer | 31,826 | Aug 17, 2026 | 1 |
| Koch Kevin | President and CEO | 52,488 | Aug 14, 2026 | 1 |
| Root Jonathan D | Director | 0Indirect | Jul 17, 2026 | 1 |
| Fox Jonathan C | Director | 24,833 | Jul 1, 2026 | 6 |
| Thompson Peter A. | Director, 10% Owner | 443,792Indirect | Jun 17, 2026 | 1 |
| Morris Arlene | Director | – | Jun 17, 2026 | 1 |
| Brege Laura | Director | – | Jun 17, 2026 | 1 |
| Edris Badreddin | Director | 19,820 | Jun 16, 2026 | 2 |
| Martin Christopher Nathan | Director | – | Jun 16, 2026 | 2 |
| Carruthers R Michael | Chief Financial Officer | 86,162 | Aug 14, 2025 | 0 |
| Blaustein Robert | Chief Development Officer | – | Aug 14, 2025 | 0 |
| OrbiMed Advisors LLC | Director, 10% Owner | 443,792Indirect | Apr 4, 2025 | 0 |
| OrbiMed Capital GP VI LLC | Director, 10% Owner | 443,792Indirect | Apr 4, 2025 | 0 |
| OrbiMed Genesis GP LLC | Director, 10% Owner | 443,792Indirect | Apr 4, 2025 | 0 |
| Semigran Marc | Chief Development Officer | 6,716 | Dec 27, 2024 | 0 |
| Novo Holdings A/S | 10% Owner | 6,071,703 | Sep 16, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jan 25, 2024 (view filing) | Jan 23 | 2 days | Carruthers R MichaelChief Financial Officer | SSale | −90.0K | $15.78 | −$1.42M | −75.6%29.0K after | 10b5-1 |
| Jan 25, 2024 (view filing) | Jan 23 | 2 days | Thompson Peter A.Director, 10% Owner | PPurchase | +454.5K | $11.00 | +$5.00M | +3.3%14.4M after | |
| Dec 28, 2023 (view filing) | Dec 26 | 2 days | Fox Jonathan CDirector | PPurchase | +10.9K | $9.30 | +$101.0K | New position10.9K after | |
| Dec 28, 2023 (view filing) | Dec 27 | 1 day | Moore John RGeneral Counsel | SSale | −8.50K | $10.50 | −$89.2K | −100.0%0 after | |
| Dec 28, 2023 (view filing) | Dec 26 | 2 days | Russell Alan JChief Scientific Officer | SSale | −172.6K | $9.33 | −$1.61M | −98.0%3.61K after | |
| May 3, 2023 (view filing) | May 2 | 1 day | Derakhshan BehradChief Business Officer | SSale | −1.75K | $8.90 | −$15.5K | −19.9%7.02K after | |
| May 3, 2023 (view filing) | May 2 | 1 day | Moore John RGeneral Counsel | SSale | −1.90K | $8.90 | −$16.9K | −22.4%6.57K after | |
| May 3, 2023 (view filing) | May 2 | 1 day | Carruthers R MichaelChief Financial Officer | SSale | −1.34K | $8.90 | −$11.9K | −7.7%16.1K after | |
| May 3, 2023 (view filing) | May 2 | 1 day | Russell Alan JChief Scientific Officer | SSale | −1.60K | $8.90 | −$14.3K | −0.9%176.2K after | |
| May 3, 2023 (view filing) | May 2 | 1 day | Donovan Joanne M.CMO | SSale | −3.25K | $8.90 | −$29.0K | −24.6%9.96K after | |
| May 3, 2023 (view filing) | May 2 | 1 day | Koch KevinPresident and CEO | SSale | −3.20K | $8.90 | −$28.5K | −30.8%7.21K after | |
| Oct 5, 2022 (view filing) | Oct 3 | 2 days | Moore John RGeneral Counsel | SSale | −4.73K | $9.76 | −$46.2K | −61.2%3.00K after | |
| Sep 16, 2022 (view filing)4:31 PM ET | Sep 16 | Same day | OrbiMed Advisors LLC and 2 othersDirector, 10% Owner | PPurchase | +484.5K | $10.32 | +$5.00M | +3.6%14.0M after | Duplicate filing |
| Sep 16, 2022 (view filing) | Sep 14 | 2 days | Novo Holdings A/S10% Owner | PPurchase | +484.5K | $10.32 | +$5.00M | +8.7%6.07M after | |
| Sep 16, 2022 (view filing) | Sep 16 | Same day | Thompson Peter A.Director, 10% Owner | PPurchase | +484.5K | $10.32 | +$5.00M | +3.6%14.0M after | |
| Sep 8, 2022 (view filing) | Sep 6 | 2 days | Moore John RGeneral Counsel | SSale | −4.73K | $10.91 | −$51.6K | −61.2%3.00K after | 2 lots |
| Aug 5, 2022 (view filing) | Aug 3 | 2 days | Moore John RGeneral Counsel | SSale | −9.23K | $9.31 | −$85.9K | −75.5%3.00K after | |
| Jul 7, 2022 (view filing) | Jul 5-6 | 2 days | Moore John RGeneral Counsel | SSale | −9.23K | $8.37 | −$77.3K | −75.5%3.00K after | 2 lots |
| Jun 21, 2022 (view filing) | Jun 16-21 | 5 days | Moore John RGeneral Counsel | SSale | −67.9K | $6.83 | −$463.9K | −95.8%3.00K after | 3 lots |
| Jun 15, 2022 (view filing) | Jun 13-15 | 2 days | Moore John RGeneral Counsel | SSale | −26.4K | $6.08 | −$160.5K | −89.8%3.00K after | 4 lots |
| Jun 10, 2022 (view filing) | Jun 8-10 | 2 days | Moore John RGeneral Counsel | SSale | −27.3K | $6.44 | −$175.8K | −90.1%3.00K after | 3 lots |
| Jun 7, 2022 (view filing) | Jun 3-7 | 4 days | Moore John RGeneral Counsel | SSale | −47.3K | $6.26 | −$296.0K | −94.0%3.00K after | 4 lots |
| May 20, 2022 (view filing)4:38 PM ET | May 18 | 2 days | OrbiMed Advisors LLC and 2 othersDirector, 10% Owner | PPurchase | +138.0K | $7.21 | +$995.0K | +1.0%13.5M after | Duplicate filing |
| May 20, 2022 (view filing) | May 18 | 2 days | Thompson Peter A.Director, 10% Owner | PPurchase | +138.0K | $7.21 | +$995.0K | +1.0%13.5M after | |
| May 18, 2022 (view filing) | May 16 | 2 days | Moore John RGeneral Counsel | SSale | −10.8K | $7.42 | −$80.1K | −78.3%3.00K after | |
| Nov 17, 2021 (view filing) | Nov 15 | 2 days | Russell Alan JChief Scientific Officer | SSale | −479 | $19.11 | −$9.16K | −100.0%0 after | 2 lots |
| Nov 12, 2021 (view filing) | Nov 9-12 | 3 days | Russell Alan JChief Scientific Officer | SSale | −69.7K | $19.91 | −$1.39M | −99.3%479 after | 7 lots |
| Nov 8, 2021 (view filing) | Nov 4-8 | 4 days | Russell Alan JChief Scientific Officer | SSale | −29.5K | $19.82 | −$583.7K | −29.5%70.2K after | 4 lots |
| Nov 3, 2021 (view filing) | Nov 1-3 | 2 days | Russell Alan JChief Scientific Officer | SSale | −44.2K | $17.88 | −$789.9K | −30.7%99.7K after | 5 lots |
| Oct 18, 2021 (view filing) | Oct 14-15 | 4 days | Russell Alan JChief Scientific Officer | SSale | −7.18K | $18.17 | −$130.5K | −4.8%143.8K after | 3 lots |
| Oct 13, 2021 (view filing) | Oct 11 | 2 days | Russell Alan JChief Scientific Officer | SSale | −1.27K | $18.02 | −$22.9K | −0.8%151.0K after | |
| Oct 8, 2021 (view filing) | Oct 6-8 | 2 days | Russell Alan JChief Scientific Officer | SSale | −21.0K | $18.39 | −$386.7K | −12.1%152.3K after | 3 lots |
| Oct 5, 2021 (view filing) | Oct 1-5 | 4 days | Russell Alan JChief Scientific Officer | SSale | −5.78K | $18.24 | −$105.4K | −3.2%173.3K after | 3 lots |
| Sep 30, 2021 (view filing) | Sep 28-29 | 2 days | Russell Alan JChief Scientific Officer | SSale | −26.5K | $17.10 | −$452.5K | −12.9%179.1K after | 3 lots |
| Sep 27, 2021 (view filing) | Sep 23-27 | 4 days | Russell Alan JChief Scientific Officer | SSale | −58.5K | $18.30 | −$1.07M | −22.2%205.6K after | 5 lots |